FIFTY-THIRD LEGISLATURE

SECOND SESSION

February 10, 2018

HOUSE FLOOR AMENDMENT number ___1__ to SENATE CORPORATIONS AND TRANSPORTATION COMMITTEE SUBSTITUTE FOR SENATE PUBLIC AFFAIRS COMMITTEE SUBSTITUTE FOR SENATE BILL 11

Amendment sponsored by Representative Elizabeth "Liz" Thomson

    1. On page 4, lines 21 through 23, strike Paragraph (4) in its entirety and insert in lieu thereof the following new paragraph:

             "(4) the prescription drug required pursuant to the step therapy protocol is not in the best interest of the patient, based on clinical appropriateness, because the patient's use of the prescription drug is expected to:

                  (a) cause a significant barrier to the patient's adherence to or compliance with the patient's plan of care;

                  (b) worsen a comorbid condition of the patient; or

                  (c) decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities.".

    2. On page 10, lines 2 through 8, strike Paragraph (4) in its entirety and insert in lieu thereof the following new paragraph:

             "(4) the prescription drug required pursuant to the step therapy protocol is not in the best interest of the patient, based on clinical appropriateness, because the patient's use of the prescription drug is expected to:

                  (a) cause a significant barrier to the patient's adherence to or compliance with the patient's plan of care;

                  (b) worsen a comorbid condition of the patient; or

                  (c) decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities.".

    3. On page 15, lines 11 through 18, strike Paragraph (4) in its entirety and insert in lieu thereof the following new paragraph:

             "(4) the prescription drug required pursuant to the step therapy protocol is not in the best interest of the patient, based on clinical appropriateness, because the patient's use of the prescription drug is expected to:

                  (a) cause a significant barrier to the patient's adherence to or compliance with the patient's plan of care;

                  (b) worsen a comorbid condition of the patient; or

                  (c) decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities.".

    4. On page 21, lines 8 through 15, strike Paragraph (4) in its entirety and insert in lieu thereof the following new paragraph:

             "(4) the prescription drug required pursuant to the step therapy protocol is not in the best interest of the patient, based on clinical appropriateness, because the patient's use of the prescription drug is expected to:

                  (a) cause a significant barrier to the patient's adherence to or compliance with the patient's plan of care;

                  (b) worsen a comorbid condition of the patient; or

                  (c) decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities.".

    5. On page 27, lines 2 through 8, strike Paragraph (4) in its entirety and insert in lieu thereof the following new paragraph:

             "(4) the prescription drug required pursuant to the step therapy protocol is not in the best interest of the patient, based on clinical appropriateness, because the patient's use of the prescription drug is expected to:

                  (a) cause a significant barrier to the patient's adherence to or compliance with the patient's plan of care;

                  (b) worsen a comorbid condition of the patient; or

                  (c) decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities.".

    6. On page 32, lines 16 through 22, strike Paragraph (4) in its entirety and insert in lieu thereof the following new paragraph:

             "(4) the prescription drug required pursuant to the step therapy protocol is not in the best interest of the patient, based on clinical appropriateness, because the patient's use of the prescription drug is expected to:

                  (a) cause a significant barrier to the patient's adherence to or compliance with the patient's plan of care;

                  (b) worsen a comorbid condition of the patient; or

                  (c) decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities.".

                                    _______________________________

Adopted ___________________ Not Adopted ________________________

          (Chief Clerk)                (Chief Clerk)

                  Date _________________